Both hepatitis A and hepatitis D infections may be associated with more advanced liver disease in patients with chronic hepatitis B

The aim of treatment of chronic hepatitis B with interferon is to induce a transition from the replicative phase of the disease to a nonreplicative state, with loss of hepatitis B virus (HBV)-DNA, seroconversion from hepatitis B e antigen (HBeAg)-positive to anti-HBe antibody-positive, and normalization of liver enzymes. The authors’ experience in 22 patients with chronic hepatitis B treated with recombinant human interferon alpha-2b (5 MU/m2 subcutaneously three times/week for 16 weeks) is reported. Before treatment all patients had been positive for hepatitis B surface antigen (HBsAg) and HBeAg for at least six months, had abnormal serum aminotransferases, had no evidence of hepatitis D or human immunodeficiency virus (HIV) infection and had compensated liver disease. Eleven of 22 patients (50%) responded to treatment with loss of HBeAg and appearance of anti-HBe antibodies, and normalization of serum aminotransferases within six months of interferon cessation. Patients were followed for 3.4±1.2 years after treatment. Ten of 11 responders remained negative for HBeAg and HBV-DNA; one patient relapsed and responded to a second course of interferon with loss of HBeAg and HBV-DNA. Seven of the 11 nonresponders underwent spontaneous (n=5) or retreatment-induced (n=2) seroconversion from HBeAg to anti-HBe and loss of HBV-DNA during follow-up. The other four nonresponders remained positive for HBeAg and HBV-DNA; three of the four progressed to decompensated liver disease. It is concluded that interferon is an effective treatment of chronic hepatitis B in 50% of patients with features similar to those used as selection criteria in the present study. These criteria probably also identify patients who have a high likelihood of spontaneous HBeAg to anti-HBe seroconversion, and it is possible that the benefit of interferon is its acceleration of this seroconversion.

Download Full-text

Antiviral therapy for chronic hepatitis B and advanced liver disease

Nature Clinical Practice Gastroenterology &#38 Hepatology ◽

10.1038/ncpgasthep0060 ◽

2005 ◽

Vol 2 (1) ◽

pp. 6-7

Keyword(s):

Chronic Hepatitis ◽

Liver Disease ◽

Hepatitis B ◽

Antiviral Therapy ◽

Chronic Hepatitis B ◽

Advanced Liver Disease

Download Full-text

Hepatitis A Seroprevalence Among Patients with Chronic Hepatitis B Infection: A Cross-Sectional Study in Iran During 2016-2017

Infectious Disorders - Drug Targets ◽

10.2174/1871526519666191009144848 ◽

2020 ◽

Vol 20 (5) ◽

pp. 748-751

Author(s):

Seyed Ali Dehghan Manshadi ◽

Neda Alijani ◽

Mohammadreza Salehi ◽

Omid Dadras ◽

SeyedAhmad SeyedAlinaghi ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Hepatitis A ◽

Cross Sectional Study ◽

University Hospital ◽

Cross Sectional ◽

Reasonable Approach ◽

The Difference ◽

Prevention Method

Introduction: The aim of this study was to determine the prevalence of exposure to hepatitis A by means of serologic markers in chronic hepatitis B patients, with the secondary aim of finding the best prevention method for hepatitis A infection in susceptible groups of our setting. Methods: During the period between 2016 and 2017, we recruited 403 hepatitis B patients aged more than 14 years and regularly attending the infectious diseases clinic at a referral university hospital, Tehran, Iran. A blood sample was collected from all the patients and tested for hepatitis A IgG. The data was analyzed by SPSS v.19. Results: Although none of the patients had previously received hepatitis A vaccine, the results for serologic level of hepatitis A IgG, demonstrated positive results in 379 (94%) cases. The mean age of patients with negative and positive IgG was 29.17 and 42.46 years, respectively; the difference was statistically significant (P≤0.001). The majority of seronegative patients were young adults aged < 25 years and 25 to 35 years (P <0.001). Conclusion: Seroprevalence of hepatitis A in chronic HBV patients in Iran is high. As HBV infected patients younger than 35 years could be seronagative for HAV infection, evaluation of these patients for HAV infection and vaccination of seronegative patients would be a reasonable approach.

Download Full-text

Dynamics of liver stiffness in chronic hepatitis B patients with concurrent metabolic-associated fatty liver disease

Journal of Hepatology ◽

10.1016/j.jhep.2021.02.013 ◽

2021 ◽

Author(s):

Danny Con ◽

Daniel Clayton-Chubb ◽

John Lubel ◽

Rohit Sawhney ◽

Stephen Bloom

Keyword(s):

Chronic Hepatitis ◽

Liver Disease ◽

Hepatitis B ◽

Fatty Liver ◽

Chronic Hepatitis B ◽

Fatty Liver Disease ◽

Liver Stiffness

Download Full-text

Update of Liver Disease Related to Chronic Hepatitis B Virus Infection.

Internal Medicine ◽

10.2169/internalmedicine.40.178 ◽

2001 ◽

Vol 40 (2) ◽

pp. 178-179 ◽

Cited By ~ 1

Author(s):

Tetsuya ISHIKAWA ◽

Shinichi KAKUMU

Keyword(s):

Chronic Hepatitis ◽

Liver Disease ◽

Hepatitis B Virus ◽

Virus Infection ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Hepatitis B Virus Infection ◽

Chronic Hepatitis B Virus ◽

B Virus

Download Full-text

Management of chronic hepatitis B before and after liver transplantation

Frontline Gastroenterology ◽

10.1136/flgastro-2016-100768 ◽

2017 ◽

Vol 9 (1) ◽

pp. 79-84 ◽

Cited By ~ 3

Author(s):

B Wang ◽

K Agarwal ◽

D Joshi

Keyword(s):

Liver Transplantation ◽

Chronic Hepatitis ◽

Liver Disease ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Public Health Problem ◽

Global Public Health ◽

Chronic Hepatitis B Infection ◽

Before And After ◽

Related Liver Disease

Chronic hepatitis B infection is a global public health problem associated with significant morbidity and mortality. Persistent infection may evolve to liver cirrhosis and hepatocellular carcinoma, and hepatitis B-related liver disease is a common indication for liver transplantation. Patients with advanced liver disease should be treated with antiviral therapy which may result in clinical improvement. The management of patients after liver transplant then focuses on preventing hepatitis B recurrence in the graft. With the introduction of prophylactic treatment, patient and graft survival has improved significantly. In this review, we will discuss the management of patients with hepatitis B-related cirrhosis, both compensated and decompensated. We also review the management of hepatitis B after liver transplantation.

Download Full-text